Market Overview - The aquaculture sector experienced a decline of 1.63% on August 27, with Tianyu Biological leading the drop [1] - The Shanghai Composite Index closed at 3800.35, down 1.76%, while the Shenzhen Component Index closed at 12295.07, down 1.43% [1] Stock Performance - Notable stock performances in the aquaculture sector include: - Zhengbang Technology (002157) closed at 3.04, up 1.67% with a trading volume of 4.3755 million shares and a turnover of 1.363 billion yuan [1] - Tianyu Biological (603717) closed at 8.31, down 6.52% with a trading volume of 228,400 shares and a turnover of 196 million yuan [2] - Other significant declines include: - Xinnong (000876) down 1.56% to 10.12 [1] - Wens Foodstuff (300498) down 2.00% to 18.11 [1] Capital Flow - The aquaculture sector saw a net outflow of 921 million yuan from institutional investors, while retail investors had a net inflow of 459 million yuan [2] - The capital flow for specific stocks indicates: - Huaying Agriculture (002321) had a net inflow of 21.13 million yuan from institutional investors [3] - ST Tianshan (300313) experienced a significant net outflow of 8.74 million yuan from institutional investors [3]

Core Viewpoint - Tianyu Bio (603717.SH) has announced a plan to issue A-shares to a specific entity controlled by its actual controller, Luo Weiguo, to raise funds for working capital and debt repayment [1][2]. Group 1: Share Issuance Details - The share issuance price is set at 6.55 CNY per share, which is 80% of the average trading price over the last 20 trading days [1]. - The maximum number of shares to be issued is 71,028,297, not exceeding 30% of the total share capital before the issuance [1]. - The total funds raised are expected to be no more than 465.2353 million CNY, which will be used entirely for working capital and debt repayment after deducting issuance costs [1]. Group 2: Changes in Control - Luo Weiguo currently holds 12.84% of the company's shares and will maintain control after the issuance, with voting rights expected to increase to 29.98% [1][2]. - The actual controller's status has changed, with Luo Weiguo now being the sole controller following the termination of the joint action agreement with Shi Dongwei [2][3]. - Shi Dongwei has resigned from the position of president and has relinquished all voting rights associated with his shares, reducing his voting rights to 0% [3][4]. Group 3: Financial Performance - For the first half of 2025, the company anticipates a net profit attributable to shareholders of 8 million to 12 million CNY, representing an increase of 28.44% to 92.66% compared to the previous year [5]. - The company has reported continuous losses over the past five years, with a net profit of -107.36 million CNY in 2024, an improvement from -461.64 million CNY in 2023 [5][7]. - The operating revenue for 2024 was 802 million CNY, a year-on-year increase of 19.55% [7].

Key Points - The article highlights significant corporate announcements and performance metrics from various companies in the industry [1][2][3][4] Group 1: Corporate Announcements - Sente Co., Ltd. (森特股份) clarified that it does not engage in "data center" related businesses [1] - Inke Recycling (英科再生) plans to invest approximately $40 million in the construction of the Vietnam Inke Qinghua (Phase III) project [1] - Daikin Heavy Industries (大金重工) signed its first overseas contract for the construction of a heavy deck transport vessel [1] - Zancaiya (咱菜雅) is planning to issue H-shares [1] - Biyimi (必易微) intends to acquire 100% equity of Xingan Semiconductor for 295 million yuan [1] - Zhongheng Group (中恒集团) has repurchased 3.5649% of its shares [1] - Nanjing New Pharmaceutical (南新制药) signed a letter of intent for acquisition with Future Pharmaceutical [3] - Pan-Asia Microelectronics (泛亚微透) plans to raise no more than 699 million yuan through a private placement [1][4] Group 2: Financial Performance - Shenghong Technology (胜宏科技) reported a net profit of 2.143 billion yuan for the first half of the year, a year-on-year increase of 366.89% [2] - Zhongji Xuchuang (中际旭创) saw a year-on-year net profit increase of 69.4% and plans to distribute 4 yuan per 10 shares [2] - Cambrian (寒武纪) achieved a net profit of 1.038 billion yuan in the first half of the year, marking a turnaround from losses [2] - China National Petroleum Corporation (中国石油) reported a net profit of 84.01 billion yuan for the first half of the year [2] Group 3: Shareholding Changes - Several companies, including Xindong Lian Ke (芯动联科) and Shenkeda (深科达), announced plans for share reductions by major shareholders [4] - Chaoyang Technology (朝阳科技) and Zhongwei Company (中微公司) also plan to reduce their shareholdings by up to 3% and 2%, respectively [4]

Core Viewpoint - Tianyu Biotechnology Co., Ltd. is issuing A-shares to specific investors, which will dilute immediate returns and affect key financial metrics, but the company has outlined measures to mitigate this impact [1][2][8]. Financial Impact Analysis - The issuance will increase the total share capital from 29,014.62 million shares to 36,117.45 million shares [5]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be -113.14 million yuan for 2024, with three scenarios for 2025: flat, 10% growth, and 20% growth [2][6]. - Under the flat scenario, basic and diluted earnings per share (EPS) will remain at -0.37 yuan, while under the 10% growth scenario, EPS will improve to -0.33 yuan [6]. - In the 20% growth scenario, EPS is projected to reach -0.30 yuan [6]. Necessity and Feasibility of the Issuance - The funds raised will be used to enhance liquidity and repay debts, improving the company's financial structure and risk resilience [8]. - The issuance aligns with the company's long-term development goals and shareholder interests [8]. Measures to Mitigate Dilution of Immediate Returns - The company plans to enhance governance structures to protect shareholder rights and ensure effective decision-making [9]. - It will implement strict management of raised funds to ensure efficient use and compliance with regulations [9]. - A profit distribution system will be established to ensure reasonable returns to shareholders, with a three-year shareholder return plan from 2025 to 2027 [11]. Commitments from Company Leadership - The actual controller and senior management have made commitments to ensure the effectiveness of measures to mitigate the dilution of immediate returns [12][12].

天域生物科技股份有限公司详式权益变动报告书 天域生物科技股份有限公司 上市公司名称： 天域生物科技股份有限公司 股票上市地点： 上海证券交易所 股票简称： 天域生物 股票代码： 603717 信息披露义务人 1： 罗卫国 上海市杨浦区国权北路 1688 弄湾谷科技园 C4 幢莱蒙 住所/通讯地址： B 座 202-203 室天域生物 信息披露义务人 2： 上海导云资产管理有限公司 住所/通讯地址： 上海市杨浦区国权北路 1688 弄 12 号 301-2 室 一致行动关系解除、原一致行动人表决权放弃、认购 股份变动性质 上市公司向特定对象发行的股票 签署日期：2025 年 8 月 26 日 天域生物科技股份有限公司详式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理 办法》《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报 告书》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收 购报告书》及其他相关法律、法规和规范性文件编写本报告书。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发 行证券的公司信息披露 ...

天域生物科技股份有限公司 上市公司名称：天域生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：天域生物 股票代码：603717 信息披露义务人：史东伟 住所/通讯地址：上海市杨浦区国权北路 1688 弄湾谷科技园 C4 幢莱蒙 B 座 股份变动性质：一致行动关系解除、表决权放弃 签署日期：2025 年 8 月 25 日 天域生物科技股份有限公司简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》《上市公司收购管理办 法》 《公开发行证券的公司信息披露内容与格式准则第15号——权益变动报告书》 及其他相关法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行 证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定，本报 告书已全面披露信息披露义务人在天域生物科技股份有限公司中拥有权益的股 份变动情况。 天域生物科技股份有限公司简式权益变动报告书 天域生物科技股份有限公司简式权益变 ...

天域生物科技股份有限公司 关于实际控制人签署《 <一致行动协议> 之解除协议》 《表决权放弃协议》暨公司实际控制人发生变更 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ? 实际控制人变更的主要内容 是否发生变更 变更前姓名/名称 变更后姓名/名称 实际控制人 ?是 ?否 罗卫国、史东伟 罗卫国 □协议转让 □司法划转/拍卖 □定向增发 证券代码：603717 证券简称：天域生物 公告编号：2025-060 □破产重整引入重整投资人 □表决权委托 变更方式（可多选） □行政划转或者变更 □一致行动关系内部转让 ?一致行动协议签署/解除/变更 □要约收购 □间接收购 ?表决权放弃 □继承 ? 天域生物科技股份有限公司（以下简称"公司"或"天域生物"）实际控制人 罗卫国与史东伟于 2025 年 08 月 25 日签署了《 <一致行动协议> 之解除协议》 （以下简 称"《解除协议》"），双方一致行动关系于《解除协议》签署生效之日起终止。同日， 史东伟辞去公司总裁职务不再直接参与公司日常经营管理， ...

Group 1 - The company raised a total of RMB 402.27 million through a private placement of 48.35 million shares at a price of RMB 8.32 per share, with a net amount of RMB 393.87 million after deducting issuance costs [1][3] - As of June 30, 2025, the balance of the raised funds in the special account was RMB 187,615.74, with an additional RMB 61.69 million remaining unutilized, accounting for 15.33% of the total raised funds [2][3] - The company plans to use the remaining funds according to the construction progress of the Tianchang Longgang Red Culture Tourism Scenic Area project, which is expected to be completed by 2025 [2][3] Group 2 - The company has approved the temporary use of idle raised funds for working capital, with amounts of RMB 130 million, RMB 220 million, and RMB 160 million used in different periods, all of which have been returned to the special account [1][2] - The internal rate of return for the Tianchang Longgang Red Culture Tourism Scenic Area project has been adjusted from 25% to 17% due to project delays, impacting the expected cumulative gross profit [2][3] - The company has confirmed that the actual use of raised funds aligns with the disclosures made in annual reports and other information disclosure documents, with no discrepancies found [2][3]

Group 1 - The company has established a three-year shareholder return plan for 2025-2027 to enhance transparency and operability in profit distribution policies [1][2] - The plan emphasizes sustainable development and considers factors such as operational performance, future development goals, and shareholder expectations [1][2] - The company aims to implement a stable and continuous profit distribution policy, prioritizing cash dividends over stock dividends [2][3] Group 2 - The company will distribute at least 10% of its distributable profits as cash dividends annually, provided it meets certain conditions [2][3] - The cash dividend proportion varies based on the company's development stage and capital expenditure needs, with a minimum of 80% for mature stages without major expenditures [3][4] - The board of directors is responsible for proposing profit distribution plans, which must be approved by the shareholders' meeting, ensuring independent directors and minority shareholders' opinions are considered [3][4][5] Group 3 - In cases where cash dividends are not proposed, the board must provide specific reasons and disclose the intended use of retained earnings [4][5] - The company will utilize online voting for shareholders during meetings to facilitate communication, especially with minority shareholders [4][5] - Any adjustments to the profit distribution policy due to significant changes in the operating environment must be proposed by the board and approved by the shareholders' meeting [4][5]

Core Viewpoint - Tianyu Biotechnology Co., Ltd. has announced that it has not faced any penalties from regulatory authorities or exchanges in the past five years, while also detailing the measures taken in response to previous regulatory actions against its controlling shareholder and a subsidiary [1][2][4]. Recent Regulatory Actions and Rectification - The company’s controlling shareholder, Luo Weiguo, received a public reprimand from the Shanghai Stock Exchange for failing to disclose changes in shareholding timely, which resulted from a dilution of shares due to a non-public stock issuance [2]. - The company was subject to administrative regulatory measures by the China Securities Regulatory Commission (CSRC) for inadequate impairment provisions related to a long-term equity investment, which violated accounting standards [2][4]. - The company has established a special rectification working group to address the issues, ensuring compliance with accounting standards and improving governance structures [3][4]. - The former financial director, Sun Weidong, received a regulatory warning for inaccuracies in financial disclosures and has since resigned from his position [4]. - The company has confirmed that its current directors and senior management have not faced any administrative penalties from the CSRC in the last three years [5].